ニューヨーク・タイムズさんのインスタグラム写真 - (ニューヨーク・タイムズInstagram)「In recent years, scientists have been chasing after drugs that might stave off heartbreak by extending the lives of our canine companions. On Tuesday, the biotech company Loyal announced that it had moved one step closer to bringing one such drug to market. Whether the drug will actually deliver on that promise is unknown. It is not available to pet owners yet, and the FDA must still review the company’s safety and manufacturing data. But conditional approval would allow the company to begin marketing the drug for canine life extension, even before a large clinical trial is complete. These developments are a sign of the accelerating pace of the science and the seriousness with which researchers and regulators are taking a field that once seemed like science fiction. They also raise questions about what it might mean to succeed, according to one expert. Are drugs like this worth it to give your pet a few more dog years? Tap the link in our bio to learn more about the longevity drugs and the science behind them. Photo by Grant Hindsley for The New York Times」11月29日 6時39分